In summary, SERPINA3C can inhibit the expression of genes associated with lipogenesis, curb lipogenesis and hepatocyte necrotic apoptosis through the JNK/NF-κB and Wnt/β-catenin signaling pathways, diminish inflammation and fibrosis in the liver, and inhibit the development of more severe NASH. The gene discussed is MAPK8; the disease is metabolic dysfunction-associated steatohepatitis.